Literature DB >> 2033346

One stage treatment of anal abscesses and fistulas. A clinical appraisal on the basis of two different classifications.

C Fucini1.   

Abstract

In a five year period 227 patients with anal abscesses and/or fistulas of suspected cryptoglandular origin were observed and treated by one surgeon. In 201 patients the primary opening or the crypt of origin of the abscesses and/or fistulas were identified. These lesions were evaluated according to two classifications [1,2]. The aim was to verify whether primary abscesses and/or fistulas may spontaneously loop all the external sphincters and the puborectalis muscle as reported by Parks et al. [1] or whether the formation of tracks which loop all the striated sphincteric complex (Parks' supra- and extra-sphincteric fistulas) derives exclusively by the incorrect treatment of more superficial lesions, as suggested by Eisenhammer. Not one of the primary suppurative lesions (acute or chronic) looped the striated sphincteric complex (external sphincter-puborectalis muscle). Supra- and extrasphincteric tracks were observed only in the lesions which recurred after previous surgical treatment. The one-stage treatment of primary abscesses and fistulas (fistulotomy drainage or one-stage lay-open) with a few exceptions is a definitive (2% recurrence rate) and safe (4% prolonged impairment of continence rate) procedure.

Entities:  

Mesh:

Year:  1991        PMID: 2033346     DOI: 10.1007/bf00703954

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  11 in total

1.  A review of the results of orthodox treatment for anal fistulae.

Authors:  R C BENNETT
Journal:  Proc R Soc Med       Date:  1962-09

2.  A classification of fistula-in-ano.

Authors:  A G Parks; P H Gordon; J D Hardcastle
Journal:  Br J Surg       Date:  1976-01       Impact factor: 6.939

3.  The treatment of high fistula-in-ano.

Authors:  A G Parks; R W Stitz
Journal:  Dis Colon Rectum       Date:  1976-09       Impact factor: 4.585

Review 4.  Anorectal abscess fistula.

Authors:  P H Hanley
Journal:  Surg Clin North Am       Date:  1978-06       Impact factor: 2.741

5.  Incidence of fistulas subsequent to anal abscesses.

Authors:  J A Scoma; E P Salvati; R J Rubin
Journal:  Dis Colon Rectum       Date:  1974 May-Jun       Impact factor: 4.585

6.  Immediate fistulotomy in the treatment of perianal abscess.

Authors:  H U Waggener
Journal:  Surg Clin North Am       Date:  1969-12       Impact factor: 2.741

7.  The final evaluation and classification of the surgical treatment of the primary anorectal cryptoglandular intermuscular (intersphincteric) fistulous abscess and fistula.

Authors:  S Eisenhammer
Journal:  Dis Colon Rectum       Date:  1978 May-Jun       Impact factor: 4.585

8.  Primary fistulectomy for anorectal abscess: clinical study of 500 cases.

Authors:  J W McElwain; R M Alexander; M D MacLean
Journal:  Dis Colon Rectum       Date:  1966 May-Jun       Impact factor: 4.585

9.  Fistulas and fistulous abscesses in the anorectal region: personal experience in management.

Authors:  J R Hill
Journal:  Dis Colon Rectum       Date:  1967 Nov-Dec       Impact factor: 4.585

10.  Rubber band seton in the management of abscess-anal fistula.

Authors:  P H Hanley
Journal:  Ann Surg       Date:  1978-04       Impact factor: 12.969

View more
  3 in total

Review 1.  Treatment-Based Three-Dimensional Classification and Management of Anorectal Infections.

Authors:  A E Ortega; K G Cologne; J Shin; S W Lee; G T Ault
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

Review 2.  German S3 guideline: anal abscess.

Authors:  Andreas Ommer; Alexander Herold; Eugen Berg; Alois Fürst; Marco Sailer; Thomas Schiedeck
Journal:  Int J Colorectal Dis       Date:  2012-02-24       Impact factor: 2.571

3.  Why do we have to review our experience in managing cases with idiopathic fistula-in-ano regularly?

Authors:  Claudio Fucini; Iacopo Giani
Journal:  World J Gastroenterol       Date:  2011-07-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.